Navigation Links
FDA approves many drugs that predictably increase heart and stroke risk
Date:5/27/2014

The agency charged to protect patients from dangerous drug side effects needs to be far more vigilant when it comes to medications that affect blood pressure.

Robert P. Blankfield, MD, MS, a clinical professor of family medicine, issues this call to the U.S. Food and Drug Administration (FDA) in an editorial published recently in an online edition of the Journal of Cardiovascular Pharmacology and Therapeutics; the print version of the article is expected to appear this autumn.

The editorial notes that several medications survived FDA scrutiny, only to be pulled from the market after reports of increased heart attacks and strokes related to use of the drugs. These include rofecoxib (Vioxx), valdecoxib (Bextra), and sibutramine (Meridia). What these drugs have in common is that they raise blood pressure. Other medications approved by the FDA, including some antidepressant medications as well as medications used to treat attention deficit hyperactivity disorder, also raise blood pressure but remain on the market despite inadequate safety data.

At issue is the apparent disconnect between what patients and doctors might consider "clinically significant" risk and the standards that some FDA reviewers apply when evaluating the safety of new therapeutics. When it comes to medications that affect blood pressure, a few FDA reviewers only classify "clinically significant" blood pressure spikes as those that raise systolic blood pressure by 20 mm Hg (milliliters of mercury) or diastolic blood pressure by 10 to 15 mm Hg.

Increases in systolic blood pressure of more than 2 mm Hg or increases in diastolic blood pressure of more than 1 mm Hg raise the risk for heart attack by 10 percent and stroke by 7 percent in middle-aged adults, according to an epidemiological study published in Lancet in 2002. Younger individuals have less risk. For example, studies published in 2011 in the New England Journal of Medicine and the Journal of the American Medical Association indicate that attention deficit hyperactivity disorder medications are safe when used by young adults. While different populations differ in terms of cardiovascular risk, Blankfield believes one point should draw broad agreement: unless one is a healthy, young adult, clinicians and patients should have adequate cardiovascular safety data before they make prescription decisions.

"It is unwise to allow medications that predictably increase risk to be marketed without adequate safety data," said Blankfield, also a family physician at University Hospitals Berea Health Center. "Risk should be quantified, and the product label should accurately communicate the risk."

Blankfield, who has published other editorials recommending that the FDA require safety data for drugs that raise blood pressure, advocates a three-step solution. First, the FDA needs to establish specific guidelines regarding what degree of blood pressure elevation constitutes a risk for different populations (i.e. young adults, middle aged adults, older adults, diabetics, hypertensives, etc.). Then the agency should require pharmaceutical companies to provide cardiovascular safety data on medications that increase blood pressure. Finally, the agency should require pharmaceutical companies to post relevant data and/or warnings on medication labels.

"This would allow physicians and patients to make informed decisions about medications," he said. "Physicians and the general public may assume that if a drug is approved by the FDA, it is safe. Yet even modest elevations in blood pressure increase the risk of heart attacks and strokes."

Blankfield was moved to write this editorial now because of the public health importance of the issue.


'/>"/>
Contact: Jeannette Spalding
jeannette.spalding@case.edu
216-368-3004
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. FDA approves first targeted drug for advanced stomach cancer
2. Augusta Maine Chocoholic, Adam Green, Approves Xocai's "Change Your Chocolate" Success to Demand for Raw Blueberry in Nagoya, Japan and Taipei, Taiwan
3. German Research Foundation approves research unit to study extreme experiences in life
4. FDA Approves Memory Shape Silicone Implants
5. Branches' Ways to Work Program Approves 60th Car Loan
6. Breast Augmentation – FDA Approves New Silicone Gel Implant
7. AOAC International Approves ORAC as First Action Official Method
8. Texas House Approves Reverse Mortgage Legislation
9. FDA Approves New Drug to Fight Advanced Prostate Cancer
10. FDA Approves Morning-After Pill Without a Prescription
11. FDA Approves New “Gummy Bear” Breast Implants, But Albany Plastic Surgeon Urges Caution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a ... the US market its advanced highly customizable contact technology solutions. , ODU Single ... advanced technologies are ideal for a wide range of applications that require customization ...
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. ... season by donating a portion of proceeds to two local organizations: North Chicago Animal ... Control & Friends is a team of authorized and trained volunteers who support ...
(Date:12/7/2016)... California (PRWEB) , ... December 07, 2016 , ... "ProBrand ... any and all media," said Christina Austin - CEO of Pixel Film Studios. , ... with easy to use drop zones. Editors can select from a variety of flip ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... December 7, 2016 According to ... titled , Global Market Study on Multiplex Detection Immunoassay: North ... , the global multiplex detection immunoassay market is expected to witness ... ... ,      (Logo: ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
(Date:12/6/2016)... 6, 2016 Homozygous Familial Hypercholesterolemia ... Summary Global Markets Direct,s latest Pharmaceutical ... Hypercholesterolemia (HoFH) – Pipeline Review, H2 2016, ... Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape. ... which is caused due to mutation from ...
Breaking Medicine Technology: